Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
MET is a member of the tyrosine kinase receptor family, which leads signal transduction from the extracellular matrix into the cytoplasm after binding its ligang, hepatocyte growth factor (HGF). The MET/HGF signaling pathway has been reported to be aberrantly activated in many human cancers, e.g., gastric cancer. In addition, amplification of MET correlates with poor prognosis, and plays a role in acquired resistance to EGFR inhibitors in patients with EGFR-mutant tumors.
The MET Genetic Alteration Cell Panel (ATCC TCP-1036) is composed of five human tumor cells that carry various degrees of MET gene copy number changes. The MET status of each cell line has been validated by ATCC. This panel is useful for studying bio-functions of MET and MET amplification, as well as tyrosine kinase inhibitor anti-cancer drug discovery.
